Physician profile
Grace J Imson
NPI 1154552180
$1,881.50
in general payments reported to CMS, 2019-2025
18 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.33 · 2020: $46.48 · 2021: $202 · 2022: $227 · 2023: $151 · 2024: $461 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.82 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $753.24 | 2020-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $222.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $208.63 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $122.62 | 2024-2025 | |
| Viiv Healthcare Company | $118.15 | 2022-2025 | Apretude |
| Lilly USA, LLC | $89.59 | 2024-2025 | Zepbound, Mounjaro |
| Coloplast Corp | $62.98 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $51.79 | 2024-2025 | Zoryve |
| Urovant Sciences INC | $42.52 | 2022 | |
| Glaxosmithkline, LLC. | $35.47 | 2024-2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $34.96 | 2021 | |
| Phadia US INC. | $29.58 | 2025 | Immunocap |
| Alnylam Pharmaceuticals INC. | $24.71 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $22.95 | 2024 | |
| Axonics, INC. | $19.10 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $16.92 | 2024 | Xdemvy |
| Phathom Pharmaceuticals, INC. | $13.32 | 2025 | Voquezna |
| Osiris Therapeutics INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Imson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.